NEWS: 公告在东京证券交易所JASDAQ标准市场新上市

表纸
市场调查报告书

临床化验服务市场 - 成长,趋势,预测

Clinical Laboratory Services Market - Growth, Trends, COVID-19 Impact, and Forecasts (2021 - 2026)

出版商 Mordor Intelligence Pvt Ltd 商品编码 922037
出版日期 内容资讯 英文 120 Pages
商品交期: 2-3个工作天内
价格
临床化验服务市场 - 成长,趋势,预测 Clinical Laboratory Services Market - Growth, Trends, COVID-19 Impact, and Forecasts (2021 - 2026)
出版日期: 2021年03月01日内容资讯: 英文 120 Pages
简介

本报告提供临床化验服务的世界市场调查,提供市场概要,各类型,各地区的市场趋势,市场规模的变化与预测,市场促进·阻碍因素以及市场机会分析,竞争情形,主要企业的简介等全面性资讯 。

目录

第1章 简介

  • 调查成果
  • 调查的前提条件
  • 调查范围

第2章 调查方法

第3章 摘要整理

第4章 市场动态

  • 市场概况
  • 成长要素
  • 阻碍因素
  • 波特的五力分析
    • 新加入厂商的威胁
    • 消费者谈判力
    • 供应商谈判力
    • 替代产品的威胁
    • 产业内的竞争

第5章 市场区隔

  • 各试验类型
    • 临床化学检验
    • 免疫检验
    • 细胞诊断检验
    • 遗传基因检验
    • 微生物检验
    • 血液检验
    • 其他
  • 各服务供应商
    • 独立型·参考实验室
    • 医院系实验室
  • 各地区
    • 北美
    • 欧洲
    • 亚太地区
    • 中东·非洲
    • 南美

第6章 竞争情形

  • 企业简介
    • Abbott Laboratories
    • Fresenius Medical Care
    • QIAGEN
    • Quest Diagnostics Incorporated
    • Siemens AG
    • Novartis AG
    • LabCorp
    • NeoGenomics
    • Charles River Laboratories
    • OPKO Health

第7章 市场机会及未来趋势

本网页内容可能与最新版本有所差异。详细情况请与我们联系。

目录
Product Code: 67131

The clinical laboratory services market was valued at USD 171.11 billion in 2020 and it is expected to reach USD 235.46 billion by 2026, registering a CAGR of 5.51% during the forecast period.

The recent outbreak of COVID-19 is expected to positively impact the clinical laboratory services industry, as the pandemic has boosted the clinical laboratory testing services. Based on the study published in National Center for Biotechnology Information in July 2020, it has been found that the current clinical diagnostics and technology, including molecular and serological testing approaches for severe acute respiratory syndrome-coronavirus 2 (SARS-CoV-2) testing has increased. There is also a rising number of developments of rapid and widespread testing through improvements in clinical diagnostics and testing technology that has helped in increasing the overall demand. In February 2021, Thermo Fisher Scientific launched the TaqPath COVID-19 HT Kit which for use on its automated amplitude platform, to increase their COVID-19 testing capacity by combining Thermo Fisher's extraction and real-time PCR instruments with liquid handling products from Tecan Group.

The market is primarily driven by the rising incidences of chronic diseases and the increasing demand for accurate and early disease diagnosis. The burden of infectious diseases and chronic disorders is constantly growing worldwide. Clinical diagnostic tests represent one of the most accurate methods to identify and characterize the various biomarkers of chronic diseases as well as for the detection of microorganisms. According to the World Health Organization (WHO) tuberculosis (TB) report in 2018, the disease was one of the top 10 causes of death worldwide. A total of 1.5 million people had died from TB in 2018 (including 251,000 people with HIV). In 2018, an estimated 10 million people fell ill with tuberculosis (TB) worldwide. 5.7 million men, 3.2 million women, and 1.1 million children were affected by this disease.

In addition, the growing burden of cancer is also expected to positively affect the demand for clinical diagnostics. According to Globocan 2020 figures, there were 19,292,789 new cancer cases diagnosed worldwide in 2020. The figures from Globocan 2020 also pointed out that the incidence of new cancer cases in very high HDI (Human Development Index) countries was 8,934,818, followed by 7,371,321 in high HDI countries. Medium and low HDI countries had 2,326,749 and 650,423 cases respectively. Owing to the increased burden of the targeted disorder, market players are focusing on technological advancements of their products, in order to have a competitive edge over the other players. For instance, in October 2019, Helena Biosciences, Belgium, launched Glyco Liver Profile at the world's first Liver Glycomics Congress to monitor and predict liver disease. Thus, these launches of the technologically advanced product coupled with increased awareness towards the early diagnosis of the disease are driving the market growth. However, stringent regulatory issues in various countries and lack of skilled labors are expected to restrain the market growth.

Key Market Trends

Independent Laboratories to Register Healthy Growth

The demand for laboratory testing is increasing, due to the increasing incidences of chronic diseases, thereby increasing the demand for the accurate diagnosis of different diseases. In highly populated and developing countries like India and China where a significant chunk of the population does not have access to proper medical diagnostic facilities, there is a huge opportunity for independent laboratories. According to National Accreditation Board for Testing and Calibration Laboratories (NABL) as of November 2020, there are around 6200 NABL accredited medical labs were present in India. Currently, the Independent laboratory segment is experiencing huge consolidation as players are focusing on strategic partnerships and collaborations which is likely to drive the growth of the market. For instance, in October 2020, U-Diagnostics, a diagnostic laboratory in the Netherlands partnered with CENTOGENE, a major provider of COVID-19 testing in Germany to provide increased COVID testing services throughout the Netherlands. Also, in July 2020, Diaceutics PLC, company focused on Diagnostic Network solution for the development and commercialization of precision medicine diagnostics patterned with Targos Molecular Pathology and HistoCyte Laboratories to enhance and expand diagnostic testing services in 2,500 labs worldwide. All these developments are fuelling the segment growth and driving the overall market.

In COVID-19 the clinical diagnostics services in independent laboratory have also exprieneced a surge in the demand of testing. There has been various COVID-19 related development that happened in the recent past that anticipated to have positive impact over the growth of the market. For instance, In October 2020, U-Diagnostics, a partnered with CENTOGENE, a major provider of COVID-19 testing in Germany to provide increased COVID testing services throughout the Netherlands.​

North America is Expected to Hold the Largest Share of the Market

The major factor driving the growth of the North American clinical laboratory services market is the presence of key players and the government organizations in the country which enables awareness among the general population and allows them to access the services conveniently. For instance, the American Clinical Laboratory Association is a not-for-profit organization that offers members the benefits of representation, education, information, and research. Also, increasing geriatric population, rising patient awareness about the value of laboratory tests, and rising prevalence of infectious and chronic disease patients are also some of the key factors driving the market growth. As per the Centers for Disease Control and Prevention (CDC), in 2018, 133 million Americans, 45% of the population has at least one chronic disease. Chronic diseases are responsible for every 7 out of 10 deaths, killing more than 1.7 million Americans every year. In addition, the high adoption of technological advancements in the country backed up by proper quality measures is playing an important role in delivering quality, efficient and effective service to the growing healthcare industry.

Competitive Landscape

The market for clinical laboratory services is highly competitive and various global, as well as local companies, are present in the market. A major share of the market is grabbed by the global players and local companies are also focusing on delivering innovative services to the people which is allowing these companies to establish their considerable place in this market. With a rising need for technology, it is expected that few new entrants will be seen in the market in the future and these players will gain a substantial share.

Reasons to Purchase this report:

  • The market estimate (ME) sheet in Excel format
  • 3 months of analyst support

TABLE OF CONTENTS

1 INTRODUCTION

  • 1.1 Study Assumptions and Market Definition
  • 1.2 Scope of the Study

2 RESEARCH METHODOLOGY

3 EXECUTIVE SUMMARY

4 MARKET DYNAMICS

  • 4.1 Market Overview
  • 4.2 Market Drivers
    • 4.2.1 Technological Advancements in the Clinical Testing
    • 4.2.2 Raised Burden of Target Diseases and Rising Demand for Early Detection
  • 4.3 Market Restraints
    • 4.3.1 Regulatory Issues
    • 4.3.2 Lack of Skilled Professionals
  • 4.4 Porter's Five Force Analysis
    • 4.4.1 Threat of New Entrants
    • 4.4.2 Bargaining Power of Buyers/Consumers
    • 4.4.3 Bargaining Power of Suppliers
    • 4.4.4 Threat of Substitute Products
    • 4.4.5 Intensity of Competitive Rivalry

5 MARKET SEGMENTATION

  • 5.1 By Test Type
    • 5.1.1 Clinical Chemistry
    • 5.1.2 Immunology
    • 5.1.3 Cytology
    • 5.1.4 Genetic
    • 5.1.5 Microbiology
    • 5.1.6 Hematology
    • 5.1.7 Others
  • 5.2 By Service Provider
    • 5.2.1 Independent and Reference Laboratories
    • 5.2.2 Hospital-based Laboratories
  • 5.3 Geography
    • 5.3.1 North America
      • 5.3.1.1 United States (By Test Type and By Service Provider)
      • 5.3.1.2 Canada (By Test Type and By Service Provider)
      • 5.3.1.3 Mexico (By Test Type and By Service Provider)
    • 5.3.2 Europe
      • 5.3.2.1 Germany (By Test Type and By Service Provider)
      • 5.3.2.2 United Kingdom (By Test Type and By Service Provider)
      • 5.3.2.3 France (By Test Type and By Service Provider)
      • 5.3.2.4 Italy (By Test Type and By Service Provider)
      • 5.3.2.5 Spain (By Test Type and By Service Provider)
      • 5.3.2.6 Rest of Europe (By Test Type and By Service Provider)
    • 5.3.3 Asia Pacific
      • 5.3.3.1 China (By Test Type and By Service Provider)
      • 5.3.3.2 Japan (By Test Type and By Service Provider)
      • 5.3.3.3 India (By Test Type and By Service Provider)
      • 5.3.3.4 Australia (By Test Type and By Service Provider)
      • 5.3.3.5 South Korea (By Test Type and By Service Provider)
      • 5.3.3.6 Rest of Asia-Pacific (By Test Type and By Service Provider)
    • 5.3.4 Middle East and Africa
      • 5.3.4.1 GCC (By Test Type and By Service Provider)
      • 5.3.4.2 South Africa (By Test Type and By Service Provider)
      • 5.3.4.3 Rest of Middle East and Africa (By Test Type and By Service Provider)
    • 5.3.5 South America
      • 5.3.5.1 Brazil (By Test Type and By Service Provider)
      • 5.3.5.2 Argentina (By Test Type and By Service Provider)
      • 5.3.5.3 Rest of South America (By Test Type and By Service Provider)

6 COMPETITIVE LANDSCAPE

  • 6.1 Company Profiles
    • 6.1.1 Abbott Laboratories
    • 6.1.2 Becton, Dickinson and Company
    • 6.1.3 BioMerieux SA
    • 6.1.4 Charles River Laboratories
    • 6.1.5 Fresenius Medical Care
    • 6.1.6 Hoffmann-La Roche AG
    • 6.1.7 Hologic Inc
    • 6.1.8 Illumina Inc.
    • 6.1.9 LabCorp
    • 6.1.10 NeoGenomics
    • 6.1.11 Novartis AG
    • 6.1.12 OPKO Health
    • 6.1.13 QIAGEN
    • 6.1.14 Quest Diagnostics Incorporated
    • 6.1.15 Siemens AG
    • 6.1.16 Thermo Fisher Scientific

7 MARKET OPPORTUNITIES AND FUTURE TRENDS